Search

everythinglearnresearchcommunity

for

Search:↓

A 21-year-old is concerned about androgenic alopecia and has been using minoxidil for a year, noticing some stabilization in the hairline but fears using it on the whole scalp due to seborrheic dermatitis. Another person suggests considering a psychiatrist for stress management, using Nizoral shampoo, and possibly trying a small dose of finasteride.

The user is very satisfied with their hair transplant results after six months, using finasteride, minoxidil, and ketoconazole shampoo. They praise Dr. Anuj and consider future touch-ups for a small untouched crown area.

The user has been using a chewable containing Finasteride, Minoxidil, and vitamins for nearly 5 months, noticing new baby hairs and increased dandruff. The chewables are from a company called Hims, and another user suggested a small hair transplant for better results.

A user discusses their hair loss and current natural treatments, including derma stamp, rosemary oil, wild growth hair oil, biotin, omega 3, and a small DHT blocker. Another user suggests the hair loss is androgenic alopecia and recommends either taking finasteride or accepting the hair loss.

A user, 42 M, NW 5-6, used oral Dutasteride, Minoxidil, RU58841 topical, micro needling, Nizoral shampoo, saw palmetto gummies, vitamin D gummies, and scalp massages for 2 months. They noticed many small light hairs on previously bald areas and are questioning if these will darken or remain vellus hairs.

The user has been treating hair loss for 7 months using a combination of pyrilutamide, a topical mix of finasteride and minoxidil, microneedling, a topical mix of GHK-Cu and minoxidil, ketoconazole shampoo, fish collagen peptides, zinc, and vitamin D3. Another user suggests that continuous small improvements could lead to significant hair regrowth over time.

A female user in her mid-20s with androgenetic alopecia and suspected telogene effluvium who has been taking Dutasteride, Spironolactone, Minoxidil, Dermarolling, Ketoconazol shampoo, and Yaz contraception for her hair loss for the past 6 months. She had a small shed during this time that she believes to be stress related.

The user has been using finasteride, minoxidil, ketoconazole shampoo, needling, and experimenting with retinol cream to treat hair loss. Despite these treatments, they observe many small vellus hairs that do not grow longer.

The user has been using finasteride, nizoral, microneedling, and recently added 3% peppermint oil to their hair loss treatment, experiencing regrowth similar to minoxidil. They suggest peppermint oil as a potentially effective, low-cost alternative or addition to minoxidil, with the added benefit of a pleasant smell and ease of use.

OP has been using finasteride for almost 2 years and is asking if it's okay to take it with vitamins like vitamin C, multivitamins, and fish oils. Another user mentions taking all vitamins together, usually with a small meal.

A user discusses their current hair loss treatment of topical minoxidil, tretinoin, and dermarolling, and considers adding topical spironolactone due to concerns about finasteride's mental side effects. Other users advise against topical spironolactone, citing ineffectiveness and unpleasant smell.

Comparing two upcoming topical hair loss treatments, Fluridil and Breezula, to determine which is most effective for treating hair loss, taking into consideration factors such as price, side effects, potential for hair growth, convenience of application, smell, greasiness, and styling after use.

Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

A user shared their positive experience with hair regrowth after two years of using finasteride, reporting no side effects. Other users discussed their experiences, including side effects like gynecomastia, and shared advice on managing potential risks.

The conversation discusses the need for a localized 5-alpha reductase inhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.

A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

The user is using topical finasteride (1MG in 30ML stemoxydine) and experiencing a lack of morning erections after three months. They are questioning whether to discontinue the treatment or if the side effect will resolve if they continue.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

The conversation discusses using RU58841 with primobolan or masteron to protect hair while on steroids, alongside dutasteride. Users suggest caution with these compounds due to potential hair loss and discuss alternatives like nandrolone and EQ for better hair safety.

Using a cap at night can prevent minoxidil from transferring to bedsheets and is safe for pets. Washing hair the next day is recommended for safety.

A 19-year-old is experiencing hair loss and considering treatments like finasteride, oral minoxidil, and possibly dutasteride. Users suggest continuing with finasteride and minoxidil, with some recommending dutasteride for stronger results.

The conversation discusses using ecklonia cava as a natural alternative to finasteride for hair loss. Users share their experiences and opinions on its effectiveness.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.